Cardiex March 2024 Quarter Update

Highlights:

• On track for record annual company revenues (>$11m).
• Inventory/production update and marketing activities ahead of commercial launch of the Pulse biometric monitor.
• CONNEQT Pulse accepted for inclusion in the American Medical Association's Validated Device Listing (VDL), affirming its clinical accuracy and reliability.
• Successful completion of HEARTsense Wearable Study validating SphygmoCor® biomarker technology in wearables.
• New patent awarded by USPTO for wearable PPG sensor technology.
• Completion of Institutional Placement.
• Completion of Entitlement Offer partially underwritten by C2 Ventures (C2V).
• Increase in the Funding Commitment Agreement (FCA) with C2V due to partial underwriting of the Entitlement Offer.
• Cash and committed funding (under FCA) > $10m to fund growth initiatives, operations and achievement of business objectives.
• Appointment of new non-executive Director.
• Extraordinary General Meeting on or shortly after 24 May to approve the FCA.
• Relisting of shares on ASX.
• Post quarter investor webinar scheduled for 24 April.
• CEO Final Comments.

On behalf of management and the Board, I am pleased to provide shareholders with an update on recent activities.

As we move towards the end of fiscal year 2024 we also move closer towards a number of significant and material milestones for the Company. Headlining this update is record Company revenue and other income of over $11m underpinned by continuing strong performance in our Clinical Trial Services Group - a revenue trend we expect to continue into FY 2025.

Click here for the full ASX Release

This article includes content from CardieX Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.